CEACAM6 is a novel biomarker in pancreatic adenocarcinoma and PanIN lesions

Mark S. Duxbury, Evan Matros, Thomas Clancy, Gerald Bailey, Michael Doff, Michael J. Zinner, Stanley W. Ashley, Anirban Maitra, Mark Redston, Edward E. Whang

Research output: Contribution to journalArticle

Abstract

Objective: The purpose of this study was to test the hypothesis that CEACAM6 expression is an indicator of adverse pathologic features and clinical outcome in pancreatic adenocarcinoma. Summary Background Data: Previously, we have demonstrated carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) to be an oncoprotein that plays an important role in the biology of pancreatic adenocarcinoma. Suppression of CEACAM6 expression reduces tumorigenesis and metastasis in vivo. Methods: A tissue microarray was constructed using tumor specimens obtained from 89 consecutive patients who had undergone pancreatic resection for pancreatic adenocarcinoma with curative intent. A second microarray containing 54 pancreatic intraepithelial neoplasia (PanIN) lesions was constructed using tissues from a separate cohort of 44 patients. Both arrays were immunostained using a specific anti-CEACAM6 monoclonal antibody. Tumoral CEACAM6 expression was dichotomized into negative and positive immunoreactivity groups. The log-rank test was used to evaluate univariate associations of CEACAM6 expression with prognosis. Survival curves were derived using the Kaplan-Meier method. Results: Tumoral CEACAM6 expression was detected in 82 (92%) pancreatic adenocarcinoma specimens. CEACAM6 expression was more prevalent in high-grade than in low-grade PanIN lesions (P = 0.0002). Negative tumoral CEACAM6 expression was associated with absence of lymph node metastases (P = 0.012), lower disease stage (P = 0.008), and longer postoperative survival (P = 0.047). Conclusions: CEACAM6 is a novel biomarker for pancreatic adenocarcinoma. CEACAM6 warrants further evaluation as both a prognostic factor and a therapeutic target in pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)491-496
Number of pages6
JournalAnnals of Surgery
Volume241
Issue number3
DOIs
StatePublished - Mar 2005
Externally publishedYes

Fingerprint

Carcinoembryonic Antigen
Cell Adhesion Molecules
Biomarkers
Neoplasms
Adenocarcinoma
Adenocarcinoma in Situ
Neoplasm Metastasis
Survival
Oncogene Proteins
Pancreatic Neoplasms
Carcinogenesis
Lymph Nodes
Monoclonal Antibodies

ASJC Scopus subject areas

  • Surgery

Cite this

Duxbury, M. S., Matros, E., Clancy, T., Bailey, G., Doff, M., Zinner, M. J., ... Whang, E. E. (2005). CEACAM6 is a novel biomarker in pancreatic adenocarcinoma and PanIN lesions. Annals of Surgery, 241(3), 491-496. https://doi.org/10.1097/01.sla.0000154455.86404.e9

CEACAM6 is a novel biomarker in pancreatic adenocarcinoma and PanIN lesions. / Duxbury, Mark S.; Matros, Evan; Clancy, Thomas; Bailey, Gerald; Doff, Michael; Zinner, Michael J.; Ashley, Stanley W.; Maitra, Anirban; Redston, Mark; Whang, Edward E.

In: Annals of Surgery, Vol. 241, No. 3, 03.2005, p. 491-496.

Research output: Contribution to journalArticle

Duxbury, MS, Matros, E, Clancy, T, Bailey, G, Doff, M, Zinner, MJ, Ashley, SW, Maitra, A, Redston, M & Whang, EE 2005, 'CEACAM6 is a novel biomarker in pancreatic adenocarcinoma and PanIN lesions', Annals of Surgery, vol. 241, no. 3, pp. 491-496. https://doi.org/10.1097/01.sla.0000154455.86404.e9
Duxbury MS, Matros E, Clancy T, Bailey G, Doff M, Zinner MJ et al. CEACAM6 is a novel biomarker in pancreatic adenocarcinoma and PanIN lesions. Annals of Surgery. 2005 Mar;241(3):491-496. https://doi.org/10.1097/01.sla.0000154455.86404.e9
Duxbury, Mark S. ; Matros, Evan ; Clancy, Thomas ; Bailey, Gerald ; Doff, Michael ; Zinner, Michael J. ; Ashley, Stanley W. ; Maitra, Anirban ; Redston, Mark ; Whang, Edward E. / CEACAM6 is a novel biomarker in pancreatic adenocarcinoma and PanIN lesions. In: Annals of Surgery. 2005 ; Vol. 241, No. 3. pp. 491-496.
@article{cebf10805296461281eb6f016aacc0bf,
title = "CEACAM6 is a novel biomarker in pancreatic adenocarcinoma and PanIN lesions",
abstract = "Objective: The purpose of this study was to test the hypothesis that CEACAM6 expression is an indicator of adverse pathologic features and clinical outcome in pancreatic adenocarcinoma. Summary Background Data: Previously, we have demonstrated carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) to be an oncoprotein that plays an important role in the biology of pancreatic adenocarcinoma. Suppression of CEACAM6 expression reduces tumorigenesis and metastasis in vivo. Methods: A tissue microarray was constructed using tumor specimens obtained from 89 consecutive patients who had undergone pancreatic resection for pancreatic adenocarcinoma with curative intent. A second microarray containing 54 pancreatic intraepithelial neoplasia (PanIN) lesions was constructed using tissues from a separate cohort of 44 patients. Both arrays were immunostained using a specific anti-CEACAM6 monoclonal antibody. Tumoral CEACAM6 expression was dichotomized into negative and positive immunoreactivity groups. The log-rank test was used to evaluate univariate associations of CEACAM6 expression with prognosis. Survival curves were derived using the Kaplan-Meier method. Results: Tumoral CEACAM6 expression was detected in 82 (92{\%}) pancreatic adenocarcinoma specimens. CEACAM6 expression was more prevalent in high-grade than in low-grade PanIN lesions (P = 0.0002). Negative tumoral CEACAM6 expression was associated with absence of lymph node metastases (P = 0.012), lower disease stage (P = 0.008), and longer postoperative survival (P = 0.047). Conclusions: CEACAM6 is a novel biomarker for pancreatic adenocarcinoma. CEACAM6 warrants further evaluation as both a prognostic factor and a therapeutic target in pancreatic cancer.",
author = "Duxbury, {Mark S.} and Evan Matros and Thomas Clancy and Gerald Bailey and Michael Doff and Zinner, {Michael J.} and Ashley, {Stanley W.} and Anirban Maitra and Mark Redston and Whang, {Edward E.}",
year = "2005",
month = "3",
doi = "10.1097/01.sla.0000154455.86404.e9",
language = "English (US)",
volume = "241",
pages = "491--496",
journal = "Annals of Surgery",
issn = "0003-4932",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - CEACAM6 is a novel biomarker in pancreatic adenocarcinoma and PanIN lesions

AU - Duxbury, Mark S.

AU - Matros, Evan

AU - Clancy, Thomas

AU - Bailey, Gerald

AU - Doff, Michael

AU - Zinner, Michael J.

AU - Ashley, Stanley W.

AU - Maitra, Anirban

AU - Redston, Mark

AU - Whang, Edward E.

PY - 2005/3

Y1 - 2005/3

N2 - Objective: The purpose of this study was to test the hypothesis that CEACAM6 expression is an indicator of adverse pathologic features and clinical outcome in pancreatic adenocarcinoma. Summary Background Data: Previously, we have demonstrated carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) to be an oncoprotein that plays an important role in the biology of pancreatic adenocarcinoma. Suppression of CEACAM6 expression reduces tumorigenesis and metastasis in vivo. Methods: A tissue microarray was constructed using tumor specimens obtained from 89 consecutive patients who had undergone pancreatic resection for pancreatic adenocarcinoma with curative intent. A second microarray containing 54 pancreatic intraepithelial neoplasia (PanIN) lesions was constructed using tissues from a separate cohort of 44 patients. Both arrays were immunostained using a specific anti-CEACAM6 monoclonal antibody. Tumoral CEACAM6 expression was dichotomized into negative and positive immunoreactivity groups. The log-rank test was used to evaluate univariate associations of CEACAM6 expression with prognosis. Survival curves were derived using the Kaplan-Meier method. Results: Tumoral CEACAM6 expression was detected in 82 (92%) pancreatic adenocarcinoma specimens. CEACAM6 expression was more prevalent in high-grade than in low-grade PanIN lesions (P = 0.0002). Negative tumoral CEACAM6 expression was associated with absence of lymph node metastases (P = 0.012), lower disease stage (P = 0.008), and longer postoperative survival (P = 0.047). Conclusions: CEACAM6 is a novel biomarker for pancreatic adenocarcinoma. CEACAM6 warrants further evaluation as both a prognostic factor and a therapeutic target in pancreatic cancer.

AB - Objective: The purpose of this study was to test the hypothesis that CEACAM6 expression is an indicator of adverse pathologic features and clinical outcome in pancreatic adenocarcinoma. Summary Background Data: Previously, we have demonstrated carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) to be an oncoprotein that plays an important role in the biology of pancreatic adenocarcinoma. Suppression of CEACAM6 expression reduces tumorigenesis and metastasis in vivo. Methods: A tissue microarray was constructed using tumor specimens obtained from 89 consecutive patients who had undergone pancreatic resection for pancreatic adenocarcinoma with curative intent. A second microarray containing 54 pancreatic intraepithelial neoplasia (PanIN) lesions was constructed using tissues from a separate cohort of 44 patients. Both arrays were immunostained using a specific anti-CEACAM6 monoclonal antibody. Tumoral CEACAM6 expression was dichotomized into negative and positive immunoreactivity groups. The log-rank test was used to evaluate univariate associations of CEACAM6 expression with prognosis. Survival curves were derived using the Kaplan-Meier method. Results: Tumoral CEACAM6 expression was detected in 82 (92%) pancreatic adenocarcinoma specimens. CEACAM6 expression was more prevalent in high-grade than in low-grade PanIN lesions (P = 0.0002). Negative tumoral CEACAM6 expression was associated with absence of lymph node metastases (P = 0.012), lower disease stage (P = 0.008), and longer postoperative survival (P = 0.047). Conclusions: CEACAM6 is a novel biomarker for pancreatic adenocarcinoma. CEACAM6 warrants further evaluation as both a prognostic factor and a therapeutic target in pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=20044385743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20044385743&partnerID=8YFLogxK

U2 - 10.1097/01.sla.0000154455.86404.e9

DO - 10.1097/01.sla.0000154455.86404.e9

M3 - Article

C2 - 15729073

AN - SCOPUS:20044385743

VL - 241

SP - 491

EP - 496

JO - Annals of Surgery

JF - Annals of Surgery

SN - 0003-4932

IS - 3

ER -